{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T20:26:37Z","timestamp":1787343997386,"version":"build-2736575974"},"reference-count":17,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"8","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Precis Oncol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>\n                      A six-gene panel involved in androgen production, uptake, and conversion (APUC-6:\n                      <jats:italic toggle=\"yes\">HSD3B1<\/jats:italic>\n                      ,\n                      <jats:italic toggle=\"yes\">HSD3B2<\/jats:italic>\n                      ,\n                      <jats:italic toggle=\"yes\">CYP3A43<\/jats:italic>\n                      ,\n                      <jats:italic toggle=\"yes\">CYP11A1<\/jats:italic>\n                      ,\n                      <jats:italic toggle=\"yes\">CYP11B1<\/jats:italic>\n                      ,\n                      <jats:italic toggle=\"yes\">CYP17A1<\/jats:italic>\n                      ) may define distinct clinical outcomes in metastatic prostate cancer. This study evaluated the prognostic and predictive value of APUC-6 expression in metastatic castration-sensitive prostate cancer (mCSPC).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>\n                      Transcriptomic data from 160 patients in the phase III Eastern Cooperative Oncology Group-ACRIN E3805 CHAARTED trial were analyzed. Patients were stratified into four subgroups based on APUC-6 and androgen receptor (\n                      <jats:italic toggle=\"yes\">AR<\/jats:italic>\n                      ) gene expression. Clinical outcomes including time to clinical progression (ttCP), time to castration resistance (ttCR), and overall survival (OS) were assessed within the androgen deprivation therapy (ADT) and docetaxel plus ADT (D-ADT) arms. Interaction testing evaluated the predictive value of APUC-6\/\n                      <jats:italic toggle=\"yes\">AR<\/jats:italic>\n                      status. Subgroup analyses were also performed by Decipher genomic risk.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      Patients with APUC-6-high\/AR-low expression showed significantly improved ttCP (hazard ratio [HR], 0.43 [95% CI, 0.22 to 0.82];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .0092), ttCR (HR, 0.56 [95% CI, 0.32 to 1];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .049), and OS (HR, 0.31 [95% CI, 0.16 to 0.61];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .0003), but did not appear to benefit from the addition of docetaxel. Conversely, APUC-6\u2013low\/\n                      <jats:italic toggle=\"yes\">AR<\/jats:italic>\n                      -low patients demonstrated significantly improved outcomes with D-ADT (ttCP: HR, 0.37 [95% CI, 0.21 to 0.65];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .00036; ttCR: HR, 0.38 [95% CI, 0.23 to 0.64];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .00017; OS: HR, 0.39 [95% CI, 0.21 to 0.72];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .0019). Statistical interaction analysis supported that patients with APUC-6\u2013low\/\n                      <jats:italic toggle=\"yes\">AR<\/jats:italic>\n                      -low expression were more likely to benefit from docetaxel (HR, 0.36 [95% CI, 0.19 to 0.66];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .001). For patients with a high Decipher genomic classifier score, those in the APUC-6\u2013low subgroup had improved survival with D-ADT, whereas those in the APUC-6\u2013high subgroup did not gain any additional benefit from docetaxel.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>\n                      APUC-6 expression and\n                      <jats:italic toggle=\"yes\">AR<\/jats:italic>\n                      gene expression define clinically relevant subgroups in mCSPC and may enhance precision medicine treatment approaches in combination with other transcriptomic biomarkers.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/po-25-01012","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T19:59:07Z","timestamp":1787342347000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["APUC-6 Genes as a Potential Prognostic and Predictive Biomarker in the CHAARTED Prostate Cancer Trial"],"prefix":"10.1200","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5320-6673","authenticated-orcid":true,"given":"Xiaolei","family":"Shi","sequence":"first","affiliation":[{"name":"Department of Hematology Oncology, University of Maryland Medical Center, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8790-7649","authenticated-orcid":true,"given":"Amol C.","family":"Shetty","sequence":"additional","affiliation":[{"name":"Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9038-4674","authenticated-orcid":true,"given":"Jarey","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2454-8498","authenticated-orcid":true,"given":"Yang","family":"Song","sequence":"additional","affiliation":[{"name":"Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4021-5909","authenticated-orcid":true,"given":"Philip A.","family":"Sutera","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5949-5058","authenticated-orcid":true,"given":"Matthew P.","family":"Deek","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2120-1939","authenticated-orcid":true,"given":"Krishnan R.","family":"Patel","sequence":"additional","affiliation":[{"name":"Radiation Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5106-8636","authenticated-orcid":true,"given":"Ravi A.","family":"Madan","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5915-1327","authenticated-orcid":true,"given":"Chad","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of GU Radiation Oncology, MD Anderson, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Proudfoot","sequence":"additional","affiliation":[{"name":"Veracyte, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elai","family":"Davicioni","sequence":"additional","affiliation":[{"name":"Veracyte, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8485-4406","authenticated-orcid":true,"given":"Arif","family":"Hussain","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology, University of Maryland Medical Center, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mass General Brigham, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0398-6018","authenticated-orcid":true,"given":"Christopher","family":"Sweeney","sequence":"additional","affiliation":[{"name":"South Australian Immunogenomics Cancer Institute, University of Adelaide, Adelaide, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella","family":"Boytim","sequence":"additional","affiliation":[{"name":"Masonic Cancer Center, University of Minnesota, Minneapolis, MN"},{"name":"Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3443-6235","authenticated-orcid":true,"given":"Kristine P.","family":"Lacuna","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles J.","family":"Ryan","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"The Prostate Cancer Clinical Trials Consortium (PCCTC), New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0031-9655","authenticated-orcid":true,"given":"Emmanuel S.","family":"Antonarakis","sequence":"additional","affiliation":[{"name":"Masonic Cancer Center, University of Minnesota, Minneapolis, MN"},{"name":"Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0147-0376","authenticated-orcid":true,"given":"Phuoc T.","family":"Tran","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Maryland, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1686-7103","authenticated-orcid":true,"given":"Justin","family":"Hwang","sequence":"additional","affiliation":[{"name":"Masonic Cancer Center, University of Minnesota, Minneapolis, MN"},{"name":"Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_7_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.0228"},{"key":"e_1_3_7_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2013.206"},{"key":"e_1_3_7_4_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12554"},{"key":"e_1_3_7_5_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00858"},{"key":"e_1_3_7_6_2","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.183158"},{"key":"e_1_3_7_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503747"},{"key":"e_1_3_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.06.003"},{"key":"e_1_3_7_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.1677"},{"key":"e_1_3_7_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2025.07.042"},{"key":"e_1_3_7_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-01105-y"},{"key":"e_1_3_7_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2019.10.002"},{"key":"e_1_3_7_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6548"},{"key":"e_1_3_7_14_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1600420113"},{"key":"e_1_3_7_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00799"},{"key":"e_1_3_7_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704174"},{"key":"e_1_3_7_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00367-1"},{"key":"e_1_3_7_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00041"}],"container-title":["JCO Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/PO-25-01012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T19:59:14Z","timestamp":1787342354000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/PO-25-01012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":17,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1200\/PO-25-01012"],"URL":"https:\/\/doi.org\/10.1200\/po-25-01012","relation":{},"ISSN":["2473-4284"],"issn-type":[{"value":"2473-4284","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"2025-10-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-08","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2501012"}}